| Literature DB >> 29423336 |
Antonio Jose Reyes1,2, Kanterpersad Ramcharan1, Stanley Lawrence Giddings2, Samuel Aboh2, Fidel Rampersad3.
Abstract
Background: Myoclonic jerks are due to sudden, brief, involuntary muscle contractions, positive myoclonus, or brief cessation of ongoing muscular activity, negative myoclonus, and may be difficult to recognize. Case Report: We describe an immunocompetent, adult, male patient with sleep-related, multifocal, myoclonic jerks and neurotoxoplasmosis with abnormal cerebrospinal fluid but normal brain imaging. There was complete resolution of the myoclonus with antitoxoplasmosis therapy after 1 week, and no relapse after 1 year. Discussion: Neurotoxoplasmosis may be subtle in presentation, difficult to diagnose, and more common than realized, and it is being increasingly implicated in epileptogenesis in humans.Entities:
Keywords: Myoclonus; epilepsy; movement disorder; toxoplasmosis
Mesh:
Year: 2018 PMID: 29423336 PMCID: PMC5803508 DOI: 10.7916/D8B86GQC
Source DB: PubMed Journal: Tremor Other Hyperkinet Mov (N Y) ISSN: 2160-8288
Video 1Demonstration of Myoclonic Jerks in our Patient. This video shows multifocal, myoclonic jerks of the patient’s head, right upper limb, fingers, and legs. These involuntary intermittent jerky movements took place during the day or night but only during sleep without causing incontinence or arousal. We found an observable pattern of three to five sequences of muscle contractions per minute, each lasting 2–3 minutes followed by a period of non- observable phenomena of 20–30 minutes’ duration. These movements occurred four to six times daily for 7 days. Myoclonus was not observed after spontaneous arousal or while the patient was awake. The patient was always unaware of those events that subsided spontaneously without benzodiazepines.
Medical Investigations
| Tests Performed on Admission | Result | Reference Range |
|---|---|---|
| WBCs | 13.8 × 109/L | 4.5–11.0 × 109/L |
| Eosinophils | 14.1% | 0.0–0.6% |
| Hemoglobin | 15.2 g/dL | 14.0–17.5 g/dL |
| Mean corpuscular volume | 83.2 fL/red cell | 80–96 fL/red cell |
| Platelet count | 350 × 103/µL | 156–373 × 103/µL |
| Serum potassium | 4.1 mmol/L | 3.5–5.1 mmol/L |
| Serum sodium | 138 mmol/L | 135–145 mmol/L |
| Serum creatinine | 0.8 mg/dL | 0.5–1.2 mg/dL |
| BUN | 11 mg/dL | 3–20 mg/dL |
| Uric acid | 4.5 mg/dL | 2.5–8 mg/dL |
| Alanine aminotransferase | 60 IU/L | 20–60 IU/L |
| Aspartase aminotransferase | 40 IU/L | 5–40 IU/L |
| Gamma glutamyl transpeptidase | 60 U/L | 8–61 IU/L |
| Lactate dehydrogenase | 330 IU/L | 105–333 IU/L |
| Alkaline phosphatase | 129 U/L | 40–129 IU/L |
| Albumin | 4.9 g/dL | 3.5–5.5 g/dL |
| Albumin-corrected calcium | 9.6 mg/dL | 9.6–11.2 mg/dL |
| CRP | 31.1 mg/dL | 0.0–1.0 mg/dL |
| Fasting blood sugar | 80 mg/dL | 60–120 mg/dL |
| VDRL test | Non-reactive | Non-reactive or reactive |
| FTA-ABS | Negative | Positive or negative |
| Elisa for HIV | Non-reactive | Non-reactive or reactive |
| Antistreptolysin O titer | 90 IU/mL | 0–200 IU/mL |
| 198 IU/mL | Positive: greater than 1.09 IU/mL | |
| Positive | Positive or negative | |
| High avidity (AI > 50%) | Low avidity (AI ≤ 50%)High avidity (AI > 50%) | |
| Herpes virus 1 IgG antibodies | Less than 0.9 | Index negative: Less than 0.9 |
| Herpes virus 1 IgM antibodies | Less than 0.9 | Index negative: less than 0.9 |
| Herpes virus 2 IgG antibodies | Less than 0.9 | Index negative: Less than 0.9 |
| Herpes virus 2 IgM antibodies | Less than 0.9 | Index negative: less than 0.9 |
| CMV IgG antibodies | 0.800 UA/mL | Negative: less than 1.5 UA/mL |
| CMV IgM antibodies | 0.778 UA/mL | Negative: less than 1.1 UA/mL |
| EBV IgG antibodies | 3.3 | Positive: Greater than 22 |
| EBV IgM antibodies | 0.1 | Negative: less than 0.8 |
| Hepatitis BsAG | Negative | Positive or negative |
| Hepatitis C IgG antibodies | Negative | Positive or negative |
| Hepatitis C IgM antibodies | Negative | Positive or negative |
| Negative | Positive or negative | |
| Anti-double stranded DNA | Negative | Positive or negative |
| Antinuclear antibody | Negative | Positive or negative |
| Perinuclear antineutrophil cytoplasmic antibodies | 5.42 U/mL | Negative: less than 10.0 U/mL |
| Cytoplasmic antineutrophil cytoplasmic antibodies | 3.73 U/mL | Negative: Less than 10.0 U/mL |
| PCR for viral infections or toxoplasmosis | Tests not obtained | Negative or positive |
| Mantoux test | Negative | Positive or negative |
| Electrocardiogram | Sinus tachycardia | Normal or abnormal |
| Chest X-ray | Normal | Normal or abnormal |
| Echocardiogram | Normal ejection fraction 75% | Normal or abnormal |
| CT scan of the brain with contrast | Normal | Normal or abnormal |
| MRI/MRA scans of the brain | Normal | Normal or abnormal |
| CSF analysis | CSF opening pressure was 14 cm of H2O. CSF contained 47 cells/mm3, 0.8 g/L of proteins, and the glucose concentration was 60 mg/dL. CSF culture showed no bacterial growth and cytology was negative for neoplastic cells. VDRL was non-reactive and India ink test for | |
| 20 IU/mL | Positive: greater than 1.09 IU/mL | |
| Positive | Positive or negative | |
| 20 IU/mL | Positive: greater than 1.09 IU/mL | |
| Positive | Positive or negative | |
| PCR for viral infections or toxoplasmosis | Tests not obtained | Negative or positive |
| Scalp EEG | Normal | Normal or abnormal |
| EMG and nerve conduction studies | Normal | Normal or abnormal |
| PCR for viral infections or toxoplasmosis in CSF | Tests not obtained | Negative or positive |
| Video-EEG, polysomnography and jerk locked backed averaging studies | Tests not obtained | Normal or abnormal |
Abbreviations: BUN, Blood Urea Nitrogen; BsAG, B surface antigen; CMV, Cytomegalovirus; CRP, C-reactive Protein; CSF, Cerebrospinal Fluid; CT, Computed Tomography; DNA, Deoxyribonucleic Acid; EBV, Epstein–Barr Virus; EEG, Electroencephalogram; ELISA, Enzyme-linked Immunosorbent Assay; EMG, Electromyography; FTA-ABS, Fluorescent Treponema Pallidum Antibody Absorption; HIV, Human Immunodeficiency Virus; Ig, Immunoglobulin; MRI/MRA, Magnetic Resonance Imaging/Magnetic Resonance Angiography; PCR, Polymerase Chain Reaction; VDRL, Venereal Disease Research Laboratory; WBC, White Blood Cell.
Medical Treatment
| Dosage | Period of Treatment | |
|---|---|---|
| Trimethoprim–sulfamethoxazole | 160 mg/800 mg 3 times daily | 2 weeks |
| Normal saline isotonic solution | 1 L daily | 1 week |
| Pantoprazole | 40 mg twice daily | 3 days |
| Carbamazepine | 200 mg 2 times daily | 6 days |
| Paracetamol | 1 g three times daily | 7 days |
| Trimethoprim–sulfamethoxazole | 80 mg/400 mg per tablet 2 tablets 2 times daily | 4 weeks initiated on day 15 |
| Pantoprazole | 40 mg once daily | 14 days initiated on day 4 |
Differential Diagnosis of the Causes of Myoclonus
| Causes | Disease states |
|---|---|
| Endocrine | Hyperosmolar hyperglycemic state |
| Ischemic states | Brain hypoxia, strokes |
| Vasculitis | CNS vasculitis |
| Autoimmune | Systemic lupus erythematosus |
| Drugs | Tramadol, morphine, hydromorphine, pethidine, quinolones, benzodiazepine, gabapentin, sertraline, lamotrigine, and any drug or chemical poisoning |
| Infection–sepsis | Neurosyphilis, HIV encephalopathy, CNS toxoplasmosis in HIV-AIDS, Lyme disease |
| Neurodegenerative | Parkinson’s disease, multiple sclerosis, Alzheimer’s disease |
| Trauma | Head or spinal cord injury |
| Neoplasia | Brain tumors |
| Mitochondrial encephalomyopathy, lipid storage disease | |
| Organ failure | Kidney or liver failure |
| Other causes | Negative myoclonus, tremor, opsoclonus myoclonus syndrome, Creutzfeldt–Jacob disease, Tourette syndrome |
Abbreviations: AIDS, Acquired Immune Deficiency Syndrome; CNS, Central Nervous System; HIV, Human Immunodeficiency Virus.